Overview

Personalized Treatment Selection for Metastatic Breast Cancer

Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if researchers can use genetic tests to predict who may benefit from treatment with SprycelTM (dasatinib) or selumetinib (AZD6244).
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
AstraZeneca
Bristol-Myers Squibb
Treatments:
Dasatinib